Marijuana-Derived drug tested for Alzheimer's agitation

NCT ID NCT05543681

Recruiting now Symptom relief Sponsor: IGC Pharma, LLC Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 31 times

Summary

This study tests whether a THC-based oral medication called IGC-AD1 can safely reduce agitation and aggression in people with mild to severe Alzheimer's dementia. About 164 participants will receive either the drug or a placebo twice daily for several weeks. The goal is to see if the drug improves behavior and eases the burden on caregivers.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Email: •••••@•••••

Locations

BayCare Health System Inc.
RECRUITING

St. Petersburg, Florida, 33705, United States
Baycrest Academy for Research and Education , University of Toronto
RECRUITING

Toronto, Ontario, ON M6A 2E1, Canada
Baylor Scott and White Research Institute
RECRUITING

Dallas, Texas, 75231, United States
Butler Hospital, Brown University
RECRUITING

Providence, Rhode Island, 02906, United States
Central Miami Medical Institute
RECRUITING

Miami, Florida, 33125, United States
ClinCloud, LLC
ACTIVE_NOT_RECRUITING

Maitland, Florida, 32751, United States
ClinCloud, LLC
RECRUITING

Melbourne, Florida, 32940, United States
Dent Neurologic Institute
RECRUITING

Amherst, New York, 02459, United States
Dominion Medical Associates, Inc.
RECRUITING

Richmond, Virginia, 23219, United States
Douglas Hospital Research Center, McGill university
RECRUITING

Montreal, Quebec, H4H 1R3, Canada
Grupo de Neurociencias de Antioquia, Universidad de Antioquia
ACTIVE_NOT_RECRUITING

Medellín, Antioquia, Colombia
Hamilton Health Sciences , Mcmaster University
RECRUITING

Hamilton, Ontario, L8M 1W9, Canada
Icahn School of Medicine at Mount Sinai
RECRUITING

New York, New York, 10029, United States
Ichor Research
RECRUITING

Syracuse, New York, 13210, United States
Instituto Sanacoop
COMPLETED

Bayamón, Bayamón, 00961, Puerto Rico
Integrative Clinical Trials, LLC
RECRUITING

Brooklyn, New York, 11229, United States
Island Health Authorities
RECRUITING

Victoria, British Columbia, V8R 1J8, Canada
Kerwin Medical Center
RECRUITING

Dallas, Texas, 75231, United States
Lynn Health Science Institute (LHSI)
RECRUITING

Oklahoma City, Oklahoma, 73112, United States
MedStar Franklin Square Medical Center Neurology
RECRUITING

Baltimore, Maryland, 21237, United States
Medstar Montgomery Medical Center
RECRUITING

Olney, Maryland, 20832, United States
Medstar Southern Maryland Hospital Center
RECRUITING

Clinton, Maryland, 20735, United States
Miami Jewish Health
RECRUITING

Miami, Florida, 33137, United States
Neurostudies Inc.
RECRUITING

Port Charlotte, Florida, 33952, United States
SCB Research Center Corp
RECRUITING

Bayamón, 00961, Puerto Rico
Senior Adults Specialty Research
RECRUITING

Austin, Texas, 78757, United States
Tandem Clinical Research GI, LLC
RECRUITING

Metairie, Louisiana, 70006, United States
Tekton Research LLC
RECRUITING

St Louis, Missouri, 63128, United States
The Alliance, Medical Sciences Campus University of Puerto Rico
RECRUITING

Rio Piedras, 00935, Puerto Rico
University of South Florida Department of Psychiatry and Behavioral Neurosciences
RECRUITING

Tampa, Florida, 33613, United States
Visionary Investigators Network
RECRUITING

Miami, Florida, 33133, United States

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

IGC-AD1 (a THC-based oral solution)

What this could lead to

If successful, this could provide a new option to ease agitation and aggression in people with Alzheimer's, potentially reducing caregiver burden.

What could go wrong

This is an early Phase 2 trial with only 164 participants, so results may not be conclusive. The treatment is THC-based, which could cause side effects like dizziness or confusion in some patients.

Conditions

The condition(s) this trial relates to.

Aggression Alzheimer disease anxiety disorder cannabis dependence Caregiver Burden dementia Depression nail-patella syndrome Psychomotor Agitation

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AGGRESSION AGITATION,PSYCHOMOTOR ALZHEIMER DISEASE CARE GIVING BURDEN CARE GIVING BURDEN NPS